About us

  Newave Pharmaceutical is a clinical-stage company dedicated to the discovery and development of innovative medicines for the treatment of hematological malignancies and autoimmune diseases. In pursuit of cutting-edge science, we are mainly focusing on clinically validated targets such as BTK, Bcl-2 and Bcl-xL and promoting international and domestic multi-center clinical development and commercialization.

  Our investigational drugs LP-168 (Rocbrutinib), LP-108 (Lacutoclax) and LP-118 have demonstrated promising efficacy with a favorable safety profile, positioning them as potential Best-in-Class (BIC) medicines. Specifically, Rocbrutinib and Lacutoclax have been granted regulatory approval by the National Medical Products Administration (NMPA) in China for pivotal registration trials.

  At Newave, we are committed to building a multinational pharmaceutical company and delivering innovative medicines to address unmet medical needs for the improvements of patient's lives.